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Medical Care Price Indexes
Robert F. Graboyes
H
ealth care expenditures have grown from 4.4 percent of the U.S. econ-
omy in 1950 to over 13 percent in 1994. At the same time, medical
care prices have risen twice as fast as other prices, according to the
Consumer Price Index (CPI). That apparent increase in the price of medical
care (relative to other goods and services) would explain by itself the additional
spending for health care, though some research suggests that the numbers not
be taken at face value. The purpose of this article is to give an understanding
of how medical care price indexes are created and why some researchers have
expressed concerns about how these indexes are interpreted.
The article is organized as follows: Section 1 introduces the notion and
purpose of a price index. Section 2 explains what is meant by quality change
and focuses on areas such as the changing efﬁcacy of a medical intervention,
the introduction of new goods, and the use of generic drugs. An additional sub-
section outlines several proposals for the difﬁcult task of constructing a valid
price index when quality changes. Section 3 explains some index problems not
associated with quality change. Section 4 summarizes the concern that today’s
indexes may overstate medical inﬂation. Finally, the appendix gives details on
some currently published indexes.
1. LOGIC AND CONSTRUCTION OF PRICE INDEXES1
A price index measures the average price of a set of goods and services in
one period against the average price of the same goods in another period. The
central logic is that this basket of goods and services provides an adequate
measure of some average purchaser’s standard of living or level of satisfaction.
This article also appears in the third edition of Macroeconomic Data: A User’s Guide, Roy
Webb, ed. (Richmond: Federal Reserve Bank of Richmond, 1994). The views expressed are
those of the author and not necessarily those of the Federal Reserve Bank of Richmond or
the Federal Reserve System.
1 Wallace and Cullison (1981) and Webb and Willemse (1994) describe in detail procedures
used and problems encountered in constructing any macroeconomic price index.
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As the price of the basket changes, the index changes proportionally. A 10
percent rise in a medical care price index thus implies a 10 percent increase in
the cost of a ﬁxed quantity of medical care for some average purchaser, even
though some individual prices will have risen and others will have fallen.
The ﬁrst task in creating these indexes is to deﬁne the limits of medical
care: Do we treat cough drops as medicine and include them, or do we call them
candy and exclude them? Do we include gymnasium membership dues, since
exercise helps prevent illness, or do we count the dues as recreational expenses
and exclude them? Once the medical sector or subsector is deﬁned, individual
medical price data can be collected. Then these data must be averaged into an
index by using some set of arithmetic weights. These weights generally reﬂect
the relative amount spent on each product in some base period. In the CPI,
hospital services receive larger weights than aspirin because consumers spend
more on hospital services than on aspirin.
2. MEDICAL CARE PRICE INDEXES AND
QUALITY CHANGE
Technological progress has changed signiﬁcantly the quality of medical care
in this century, and this is the fundamental complication in producing medical
care price indexes. Implicitly, a price index assumes that one’s consumption
basket does not change over time and a given basket provides a constant level
of satisfaction. While these assumptions are never strictly true for any set of
commodities, they are especially problematic in medicine. The treatments given
in 1944 barely resemble those given in 1994. And the health beneﬁts of a given
treatment can change through the years as well.2
The productivity of medical care has advanced greatly over this century.
Some of the types of technological progress include the following: [1] Previ-
ously untreatable disease becomes treatable: In recent decades, heart trans-
plants and coronary bypass operations have given years of life, whereas earlier
patients would have died. Therapies such as antibiotics, beta blockers, insulin
therapy, and kidney dialysis have effected similar improvements. [2] Previous
treatment replaced by new treatment: Laparoscopic techniques, using ﬁber
optics and tiny incisions, have largely replaced traditional open surgery in many
areas. For example, newer techniques for gallbladder removal require only one
to two days in the hospital, compared with three to seven days for traditional
surgery. The laparoscopic procedure also results in fewer postoperative compli-
cations, less pain, and a shorter convalescence. In addition, some patients for
whom traditional surgery is too risky can safely undergo the newer technique.3
2 For example, the expected beneﬁt of a heart transplant is much higher in 1994 than it was
in 1970, when the operation was still experimental.
3 Legorretta et al. (1993).       
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[3] Cheap prevention of costly diseases: Vaccines against polio, smallpox,
and other diseases have provided relatively inexpensive means to eradicate
diseases that, if contracted, would impose tremendous costs. [4] Decreased
resource requirements for an existing treatment: Electronic monitors allow
some conditions to be tracked at home rather than in a hospital bed, thus
reducing the need for hospital resources. Some cost reductions have resulted
more from a change in medical opinion than in any change in technology; for
instance, doctors now recommend shorter hospital stays following childbirth.
[5] Movement up the learning curve: Since the ﬁrst coronary bypasses were
performed, practice and observation have made surgeons more adept at the
procedure, resulting in higher success rates.
In some areas of medicine, however, a given level of medical spending
may now provide fewer health beneﬁts than in the past. Defensive medicine—
care that does not beneﬁt the patient and whose purpose is to avoid malpractice
claims—has become a ﬁxture of American medicine.4 The health beneﬁts of
other procedures are hotly debated—prostate and breast cancer screenings are
examples. Heroic end-stage care for the terminally ill is another. A ﬁnal com-
plication in measuring the quality of medical care is that the population being
treated and the illnesses people suffer change over time. It is impossible to
neatly compare the productivity of a medical system pre- and post-AIDS, for
example.
Quality changes such as these complicate the construction and interpreta-
tion of medical care price indexes. Some examples discussed below illustrate
difﬁculties encountered when [1] the efﬁcacy of a good or service changes,
[2] new goods are introduced, and [3] old goods are reintroduced under new
labels.
Change in Efﬁcacy
Over time, the improved health from using a speciﬁc medical commodity often
increases (or decreases). This section uses a hypothetical example to demon-
strate the analytical difﬁculties posed by changes in the quality of medical
care. Table 1a shows data on a hypothetical economy in which gross domestic
product (GDP) consists of two goods: medical procedures (say, an operation)
and food. From year 0 to year t, nominal GDP (the sum of spending on food
and medicine) grows from $9.5 million to $12.2 million. As the expenditures
index shows, total purchases have grown 28 percent.
Table 1b uses an alternative measure of medical output. Instead of deﬁning
output as the number of procedures performed, this table deﬁnes it as the
number of lives saved (alternatively, we could use quality of life or some other
measure of medical outcome). According to these ﬁgures, there has been a
4 Brostoff (1993) describes a study by Lewin-VHI, Inc., that estimated the costs of defensive
medicine to be $36 billion per year.             
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Table 1a Measuring Aggregate Price and Quantity Changes:




(year 0 = 100)
Year 0
Expenditures 500,000 9,000,000 100
Quantity 1,000 100,000 100
Price 500 90 100
Share of economy 5.3% 94.7%
Year t
Expenditures 1,200,000 11,000,000 128
Quantity 2,000 110,000 115
Price 600 100 112
Share of economy 9.8% 90.2%
Interpretation: Index = 128 implies 28 percent growth over the period. Calculation of
year t indexes:
Expenditure: 128 ≈ 100 ×
1,200,000+11,000,000
500,000+9,000,000
Price: 112 ≈ 100 × (5.3% ×
600
500 + 94.7% ×
100
90 )
Quantity: 15 ≈ 100 ×
Expenditure Index
Price Index
dramatic quality change in the medical procedure. Thirty percent of the patients
survive in year t (600 out of 2,000), compared with only 10 percent in year
0 (100 out of 1,000). Because of this, the price of one life saved has dropped
from $5,000 to $2,000, compared with an increase in the price per procedure
from $500 to $600.
Inﬂation is measured in Table 1b as 7 percent, compared with Table 1a’s
rate of 12 percent. Real economic growth is 15 percent in Table 1a and 20
percent in Table 1b. The practical effects of such measurement discrepancies
are not trivial. Throughout the economy, wage contracts, government beneﬁts,
taxes, and other contractual arrangements tie payments to changes in the general
price level. It matters to a company whether its workers should be given a 12
percent or a 7 percent cost-of-living increase.
For most purposes, it would be better to measure growth as in Table 1b
rather than as in Table 1a, since it is lives saved and not procedures performed
that indicate economic well-being. We can guess, for example, that improve-
ments in X-ray machines and in doctors’ abilities to read X-rays have led to a
greater efﬁcacy in the use of X-rays. How much sooner, on average, are            
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Table 1b Measuring Aggregate Price and Quantity Changes:




(year 0 = 100)
Year 0
Expenditures 500,000 9,000,000 100
Quantity 100 100,000 100
Price 5,000 90 100
Share of economy 5.3% 94.7%
Year t
Expenditures 1,200,000 11,000,000 128
Quantity 600 110,000 120
Price 2,000 100 107
Share of economy 9.8% 90.2%
Interpretation: Index = 128 implies 28 percent growth over the period. Calculation of
year t indexes:
Expenditure: 128 ≈ 100 ×
1,200,000+11,000,000
500,000+9,000,000
Price: 107 ≈ 100 × (5.3% ×
2,000
5,000 + 94.7% ×
100
90 )
Quantity: 120 ≈ 100 ×
Expenditure Index
Price Index
cases of disease found in 1994 than in 1954 on a per-X-ray basis? How much
more does the average X-ray extend or improve life today? Even if we could
accurately answer these questions, what would be the dollar value of each
improvement? Since the answers are difﬁcult to even approximate, analysts in
statistical bureaus with limited budgets usually shrug their shoulders and use
the number of X-rays to represent output, rather than using some measure of
abatement of disease or extension of life.
The difﬁculty in distinguishing quality, quantity, and price changes exists
for all goods and services. For example, a pound of chicken in 1994 is not the
same product as a pound of chicken was in 1924. The taste, consistency, and
nutritional characteristics have all changed. Also, the qualities of a computer in
1994 are vastly different from what they were in 1974. At least for these tan-
gible products, one can imagine how quality might be deﬁned. With services,
however, the difﬁculty in deﬁning output makes it especially problematic to
measure changes in the quality of that output. In no service industry is the
effort more daunting than in medicine. Measuring medical care production in
terms of the means (procedures) rather than the ends (good health) is somewhat     
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akin to measuring vegetable prices in dollars per acre planted rather than dollars
per bushel of yield. The former would lead us to mistakenly measure increased
yields per acre from added fertilizer as inﬂation.
New Goods Problem
Another serious indexing problem is that new products and technologies have
been introduced rapidly into medicine (and other industries) in the last 50 years.
Price index weights, however, are revised only infrequently. As a result, price
indexes may miss signiﬁcant reductions in the cost of living. Gordon (1992)
writes that “penicillin entered the CPI in 1951, after it had already experienced
a 99 percent decline from its initial price” (p. 9). Berndt, Griliches, and Rosett
(1993) examined the new goods problem with respect to the introduction of new
pharmaceuticals. They found that the Bureau of Labor Statistics (BLS) tends
to give insufﬁcient weight to newer products and that these products tend to
experience lower-than-average price increases. Together, these two tendencies
would bias the measured price increases upwards.
We can illustrate the mechanics of the new goods problem by departing
from medicine for a moment and considering two familiar products from the
electronics industry. Suppose a long-term price series used 1940 expenditure
weights. There would be no weight for the transistor, and the skyrocketing price
of vacuum tubes would appear to contribute to inﬂation. Of course, vacuum
tube prices are up largely because the production volumes have become small.
The invention of the transistor has greatly reduced the cost of devices that
amplify and rectify electronic signals.
While the BLS deals with the new goods problem in several ways, the
most common process is called “linking” in which, at some arbitrary point, one
good is dropped and the other added. Importantly, the new good is introduced
in such a way that this replacement leaves the price level unchanged.
The data in Table 2 provide a hypothetical example of linking. Suppose
drug A is replaced over time by drug B, but that for a time both are on the
market. The ﬁrst two columns represent the prices of drug A and drug B in years
1 through 6. The price of drug A is rising due to general inﬂation and other
factors. New products like B frequently will decline in price after introduction
because [1] through experience the company entering the market improves its
manufacturing techniques, [2] the new company increases its market share and
can take advantage of economies of scale, and [3] close substitutes increas-
ingly compete with proﬁtable established products. The next-to-last column
represents a price index that, beginning in year 2, reﬂects changes in the price
of drug B. The last column represents an index that reﬂects drug A prices until
year 5 and then switches to drug B. The problem is deciding at what point
to drop drug A and to add drug B. This table shows that such a choice may
completely change the message sent by the price index. Again, this problem        
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1 100 420 100 (base year) 100 (base year)
2 130 390 93 ≈ 100 × 390 ÷ 420 130 ≈ 100 × 130 ÷ 100
3 140 370 88 ≈ 93 × 370 ÷ 390 140 ≈ 130 × 140 ÷ 130
4 160 340 81 ≈ 88 × 340 ÷ 370 160 ≈ 140 × 160 ÷ 140
5 190 380 90 ≈ 81 × 380 ÷ 340 179 ≈ 160 × 380 ÷ 340
6 240 470 112 ≈ 90 × 470 ÷ 380 221 ≈ 179 × 470 ÷ 380
Notes: If drug B replaces drug A in the price index in year 2, the index shows a smaller price
rise than if B replaces A in year 5. This is because the year 5 link misses drug B’s price decline
in the ﬁrst few years. Calculations are not exact due to rounding.
may be more serious in medicine than in most other sectors of the economy.
The relative costs and beneﬁts of transistors and vacuum tubes can be deﬁned
in fairly objective terms, while new drugs are rarely as easy to compare.
Old Goods, New Label Problem—Generic Drugs
A variant on the new goods problem is the case in which an existing good is
reintroduced to the market under a new label, as in the case of generic drugs.
Following is a hypothetical example illustrating the generic drug problem de-
scribed by Scherer (1993). Suppose that [1] a name-brand drug X costs one
dollar per pill, [2] a biochemically identical generic drug Y is introduced at
ﬁfty cents per pill, [3] half the market switches from X to Y. If one treats X
and Y as a single drug, then the average price has dropped by 25 percent, since
purchasers of the pills are now paying 25 percent less on average than they
used to.
In fact, this change will not normally show up in the CPI as a price re-
duction. First, weights in the CPI market basket are changed infrequently. CPI
data are collected on speciﬁc brands, like our drug X. Until the weights are
revised, the price of brand Y will not enter into the calculation of the CPI.
Second, when the generic drug Y is added to the CPI market basket, it will
be added into the index as a new product, separate from name-brand drug X.
Thus, the addition of Y to the basket will not show up as a decline in price.
Price indexes indicate generally that pharmaceuticals prices have risen at a
high rate compared with general inﬂation or even with other parts of the med-
ical sector. Scherer (1993), Berndt, Griliches, and Rosett (1993), and Griliches
and Cockburn (1993) examine this trend and conclude that mismeasurement
is partly to blame. This mismeasurement occurs in part because of the way
generic drugs are introduced into indexes such as the CPI.       
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Alternative Approaches to Measuring Medical Care Prices
Researchers have suggested alternative ways of measuring medical output that
might yield better estimates of medical prices than do current procedures.
Wilensky and Rossiter (1986) describe four ways of measuring medical care
output: the procedure (e.g., one day’s radiation therapy), the case (e.g., a cancer,
from diagnosis to conclusion of treatment), the episode (e.g., a particular period
of the illness), and per capita (e.g., the patient’s total health care, including the
cancer). Procedure-based indexes are the most commonly used today, but alter-
native indexes have been proposed that would use alternative units of output.
Health Insurance Premiums as Price Proxies
Some researchers have suggested that a good indicator of price increases might
be found in the premiums paid on a standard health insurance policy.5 The
logic is that an insurance policy represents a ﬁxed bundle of medical goods and
services, and if quality remains constant, the price of the policy will represent
the price of that bundle. This idea found some favor in the late 1960s, when,
it can be argued, health insurance policies were fairly standardized. Problems
with that approach have become apparent, however, as policies have grown less
uniform, with broad differences in copayments, deductibles, payout limits, and
services provided. Technological and other changes in medicine mean that a
policy today provides very different care from an identical policy 30 years ago;
thus, quality changes are as big a problem as they are with a procedure-based
measure. Also, the real values of policies differ across states, since each state’s
regulatory practices partially determine the insurance companies’ liabilities.
Finally, the quantity of medical care demanded by the average policyholder
differs across localities.
Costs of Treatment of a Representative Group of Illnesses
Scitovsky (1964) proposed taking a group of illnesses and measuring how the
prices of treating those illnesses changed over time.6 Instead of measuring
inputs like hospital beds, operations, and drugs, this approach would take an
occurrence of a number of illnesses—say, a case of pneumonia, a brain tumor,
and a broken leg—and measure the total costs of treating this set of illnesses.
Quality change would still be a problem, though, since the means of treating
a particular disease changes over time. This proposal did suggest adjusting the
measured treatments for quality, using indicators like infant mortality and age-
adjusted death rates per numbers of cases as proxies for quality. Scitovsky was
5 This idea is discussed in Feldstein (1993), pp. 71–72. Feldstein also refers readers to Reder
(1969), p. 98, and Barzel (1969).
6 This proposal is described in Feldstein (1993), pp. 64–71.       
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concerned, however, that simple quality adjustments such as these would be
inadequate, given the complexity of measuring medical outcomes.
Hedonic Pricing
One method of adjusting for quality that has been used by statistical agencies
and academic researchers is hedonic pricing. Hedonic pricing values a good by
assuming that the good is really a bundle of characteristics and that there are
separate demands for each of these characteristics. In measuring price changes
in computers, for example, the Bureau of Economic Analysis uses a model that
breaks the computer down into a set of characteristics (e.g., number of calcu-
lations per unit of time), and then measures the prices of those characteristics.
Recombining these separate prices yields an estimated price for a computer,
holding quality constant (see Triplett [1986]). In this approach, quality is merely
the sum of a group of quantities.
An example of the hedonic approach applied to medical equipment is
Trajtenberg (1990). He compares three price indexes for Computerized Tomo-
graphic X-ray devices (CT or CAT scanners): [1] a standard index with no
adjustment for quality change; [2] a hedonic index, assuming that a CAT
scanner is really a bundle of four characteristics (head vs. body, scan time,
resolution, and image reconstruction time); and [3] a welfare-change index
based on the same four characteristics, but designed for a very different
objective—measuring the consumer’s well-being rather than the price of these
four characteristics. Over the period 1973 to 1982, the standard index increases
from 100 to 259.4, the hedonic price index decreases from 100 to 27.3, and
the welfare-change index decreases from 100 to .07. Thus, one methodology
produces a price index 3,700 times higher than does another price index. As
Getzen (1992) writes:
Differences of this magnitude in only a few items would be sufﬁcient to
show that rather than being the fastest rising component of the [general price
level], the real quality-adjusted price of medical care is falling—a conclusion
that would be conﬁrmed by most rational consumers given a choice of 1931
medicine at 1931 prices and the medical technology of 1991 at 1991 prices.
(P. 116)
Hedonic pricing may provide a promising approach for some goods. However,
the procedure adds markedly to the cost of data, and not all goods and services
are good candidates for the procedure.
3. OTHER PROBLEMS
The passages below describe several index problems not associated with quality
changes. They include [1] the use of list prices instead of transaction prices,
[2] statistical sampling problems, [3] the measuring problems introduced by
health insurance policies, and [4] substitution bias.      
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Transaction Versus List Prices
Price indexes may sometimes use data from list prices rather than actual trans-
action prices. Ideally, price indexes should include only transaction prices. In
many medical care transactions, the discrepancies are large. For example, a
hospital bill may state the charge for a procedure as $600, but Medicare may
reimburse the hospital only $400. If the hospital receives no additional com-
pensation from the patient or from private insurers, then $400 should be the
price of the procedure used in compiling the price index. Unfortunately, it is
often the case that list prices are easier to come by than transaction prices, so
it is these ﬁctional list prices that are used in the index.
If discounts (or the ratio of list to transaction prices) were constant over
time, this problem would not be particularly pernicious. Medical discounts,
however, have grown rapidly over recent decades, so the use of list prices
appears to have imparted an upward bias to reported increases in medical care
prices.7
Sampling Problems
In a world of costless data collection, an ideal index of medical care prices
would incorporate the price of every single medical transaction that actually
takes place, down to every individual box of aspirin sold. Collecting one price
for each individual transaction, though, is impractical or impossible, so the pro-
ducer of a price index must drastically reduce the number of prices collected by
sampling. Instead of measuring the price of every single aspirin purchased in
America in October, the statistician can more readily measure only the list price
for brand X aspirin at ﬁve stores each in one hundred localities on October 12.
The effects of such sampling are not neutral, and the sample may therefore mis-
represent the total aspirin purchases nationally. Analysts have identiﬁed several
ways in which typical procedures could distort price indexes. For example, list
prices may be higher than actual prices paid because of routine store discounts.
Much aspirin may be purchased by bulk users such as clinics who pay less than
list prices. Brand X may be higher-priced than store brands. The localities and
stores selected may be unrepresentative. And Columbus Day may be a poor
day to sample prices because many stores will have one-day discounts.
Medical Insurance
Getzen (1992, p. 85) notes that the problem of measuring medical prices is fur-
ther complicated by medical insurance. Most medical payments in the United
7 For example, the hospital component of the CPI, which uses list price data, consistently
rises faster than does either the HCFA Hospital Transaction Output Price Index or the PPI Hospital
Services Index, both of which use transaction price data (see Table 3). Bottiny (1993, p. 32) cites
ﬁgures showing that from 1984 to 1988, California hospital list prices (charges billed) increased
by 11.1 percent annually, while transaction prices increased by 7.0 percent.        
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States are made through public or private insurance policies. Payments under
these policies make it difﬁcult or impossible to separate out the prices paid
by speciﬁc individuals for speciﬁc procedures. Insurance has exacerbated the
problem of “cost-shifting.” This problem arises when one group of patients
is charged more than the full cost of treatments in order to subsidize another
group whose charges do not fully cover treatment costs. Health care providers
often make up losses on Medicare and Medicaid patients by raising prices
to other patients, thus causing some prices to be overstated and others to be
understated. If (as with the medical component of the CPI) the sample mostly
measures payments by non-Medicare, non-Medicaid patients, then an increase
in cost-shifting will impart an upward bias to the index.
Choice of Weights and Substitution Bias
A price index is simply a weighted average of prices, and the weights are
generally derived from the mix of items consumed across the economy. The
consumption mix, though, changes dramatically over time in response to shifts
in relative prices and other factors, and the choice of weights is important. In
Table 1b, medical expenditures rise from 5.3 percent of output to 9.8 percent.
Based on year 0 weights (5.3 and 94.7 percent), the price level rises from 100 to
107. Based on year t weights (9.8 and 90.2 percent), however, the price level
would rise from 100 to only 104 (9.8 percent × 2000/5000 + 90.2 percent
× 100/90). In the U.S., most price indexes use the ﬁrst method, infrequently
changing weights.
A general principle in economics is that as the price of one good rises,
consumers tend to shift at the margin out of that good and substitute into
other goods whose prices are falling or rising more slowly. In Table 1b, for
example, the shift in spending toward medical procedures may result from the
decline in the price of one life saved relative to the price of one unit of food
purchased. With ﬁxed expenditure weights, these demand shifts will be missed
and the price index will give too much weight in later years to the good whose
price is rising fastest, a statistical phenomenon known as substitution bias. As
a practical matter, substitution bias appears to be fairly small in most price
indexes and is dwarfed by quality-measurement problems.
4. SUMMARY: RISING EXPENDITURES VERSUS
RISING PRICES
This article has explained why some researchers suspect that the CPI and other
indexes systematically overstate (or, possibly, understate) the rise in medical
prices, though the case is difﬁcult to quantify with any precision. True medical
outputs (the number of lives saved, improvement in patients’ quality of life,
relief from pain, etc.) are difﬁcult or impossible to measure. For this reason,     
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statisticians usually substitute quantities of inputs (number of coronary bypasses
performed, number of hospital days), treating them statistically and semanti-
cally as if they were outputs. To some extent, this problem of disentanglement
exists for all goods and services, but the undeniable but difﬁcult-to-quantify
progress in health care implies that the problem must be especially troubling
in medicine. [See next page for a listing of papers and articles on this subject.]
Quality changes in medical care compound the problem, since a price index
implicitly assumes that the quality of the underlying good or service does not
change over time. In medicine, evolving technology and treatment regimes
have steadily increased the quality of medical care over the past half century.
To the extent that price indexes overstate medical inﬂation, these errors, in
turn, will cause price indexes like the CPI to overstate general inﬂation. And
the impact of any such errors may grow in the future because, according to
some projections, medical care may grow from the present 13 percent of the
national economy to 20 percent by 2010.
Perhaps the largest cost of measurement errors would be inappropriate
policy decisions. Much of the present debate on health care reform is premised
on the “fact” that medical prices have grown faster than those of most other
goods and services. One can imagine that today’s health policy debate and
proposals would be very different were there a general perception that medical
prices were growing slowly.
APPENDIX
A REFERENCE GUIDE TO PUBLISHED INDEXES
A number of price indexes are produced, each based on a segment of national
health expenditures (NHE). The Consumer Price Index (CPI) is perhaps the
best-known measure of aggregate price changes in the U.S. economy. Sim-
ilarly, the Medical Care Price Index (MCPI), the medical component of the
CPI, is the best-known measure of price changes in the medical sector and is
often cited as representing “the” rate of inﬂation in medical care. It should be
noted, however, that the MCPI covers a basket of goods and services that in
many ways is unrepresentative of national health expenditures, as is explained
later in this section.
Numerous other indexes measure medical care price changes—some in
narrower ranges of transactions than those entering the MCPI, and some in
broader ranges. The MCPI, however, must be considered the paramount medical
price series. Data from the MCPI are used as proxies for prices and weights in
producing most other medical care price series. Thus, whatever problems exist
in the MCPI ﬁlter through into almost all other series. Many series also borrow    
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The following papers and articles discuss possible sources of biases in medical
price series. The majority, though not all, presume that the biases are upward.
Article Concerns Addressed Include
Armknecht and Ginsburg (1990) The CPI may understate medical
insurance cost increases.
Berndt, Griliches, and Rosett (1993) The CPI fails to incorporate price de-
creases associated with generic drugs.
Bottiny (1993) The CPI may overstate medical inﬂation
because of [1] the exclusion of most
government health expenditures (which
have risen less than private payments)
from the MCPI, [2] substitution bias,
and [3] the heavy reliance on list
prices rather than transaction prices.
Cleeton, Goepfrich, and Weisbrod (1992) Lags in introducing new drugs, plus
the lack of information on effective-
ness and safety of drugs, may bias
the CPI either upwards or downwards.
Getzen (1992) Traditional price indexes are not suit-
able for use as deﬂators of health
expenditures.
Griliches and Cockburn (1993) The CPI fails to incorporate price de-
creases associated with generic drugs.
Kroch (1991) The CPI fails to adjust for changes
in the quality of medical care associ-
ated with, for example, hospital room
modiﬁcations, nurse-to-patient ratios,
and introduction of new technologies.
Lebow, Roberts, and Stockton (1992) The CPI fails to incorporate price de-
creases associated with new goods.
Madigan (1991) The CPI fails to adjust for improve-
ments in the quality of medical care.
Newhouse (1988) The source of medical expenditure
increases cannot be determined
because the CPI [1] measures the
prices of inputs, not outputs, [2] uses
list prices, not transaction prices,
[3] largely ignores technological change,
and [4] uses inappropriate weights.
Scherer (1993) The CPI has shortcomings in how it
absorbs generic drugs, new products,
and quality improvements.
Trajtenberg (1990) Because of quality changes, the CPI
may dramatically overstate increases
in CAT scanner prices.
Tregarthen (1993) The CPI relies on list prices and fails
to adjust for quality changes.     
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data from other series produced by the Department of Labor, the Department of
Commerce, the Health Care Financing Administration, the American Medical
Association, the American Hospital Association, and others. So, all the medical
care price series tend to share many of the same methodological problems.
The following section contains comparative information on a number of
currently available medical care data series. Entries generally include the fol-
lowing sections:
Coverage: The basket of goods and services whose average price the index
measures
Purpose: The reason for producing the index
Years/Periodicity: The years of available data and the periodicity (e.g.,
annual, quarterly, monthly)
Source: The organization that produces the index
Reported: The publication in which data can be found
References: Articles or books explaining the index
Miscellaneous: Other pertinent information
Historical data on these series are found in Table 3.
Medical Care Price Index (MCPI)—Coverage: A basket of goods and
services representing consumers’ out-of-pocket medical expenditures—roughly
20 percent of the expenditures included in national health expenditures. Does
not include most medical costs paid for by public or private insurance programs.
Includes health insurance premiums paid directly by the consumer, but not those
paid by employers or governments. Purpose: Comprises part of the Consumer
Price Index (CPI). The CPI is widely used as a benchmark for adjusting con-
tractual payments, including wage and Social Security payments, for inﬂation.
Years/Periodicity: 1936–1946/quarterly; 1947–present/monthly. Source: U.S.
Department of Labor, Bureau of Labor Statistics. Reported: In Monthly Labor
Review. References: BLS Handbook of Methods (1992, ch. 19); Getzen (1992);
Feldstein (1993). Miscellaneous: The absence of payments made by public and
private insurance policies is a weakness if one is using the MCPI as a proxy for
overall medical inﬂation; however, the MCPI is not produced with that purpose
in mind.
National Health Expenditures (NHE) Deﬂator—Coverage: All medical
care goods and services included in National Health Expenditures, a mea-
sure of total medical care spending. Purpose: To measure price movements
in the entire medical sector. Years/Periodicity: Series under development as
of November 1994. Source: Health Care Financing Administration (HCFA).















































































































CPI 3.9%∗ 1.3% 4.3% 7.5% 4.0% 1935–93
MCPI 2.8%∗ 3.2% 6.1% 7.9% 7.5% 1935–93
Medical Care Commodities 2.7%∗ 0.7% 0.3% 4.9% 7.1% 1947–93
Professional Medical Services 5.8%∗ 7.4% 6.5% 1967–93
Dental Services 3.1%∗ 2.3% 5.4% 6.9% 6.5% 1935–93
Eye Care 3.8%∗ 1986–93
Hospital and Related Services 11.7%∗ 9.0% 1977–93
NHE Deﬂator Data series under development as of November 1994
PCE, Fixed-Weight, Medical Component 2.5% 3.4% 6.6% 7.8% 6.7% 1929–93
PHCE Deﬂator 2.3%∗ 5.4% 7.4% 7.1%∗ 1960–91
MEI 3.7% 1980–93
AHA Hospital 3.2%∗ 6.4% 8.0% 6.7% 1963–93
HCFA PPS Hospital 4.6% 1980–93
HCFA Hospital Transaction Output Price Index 3.5%∗ 6.6% 8.2% 6.7% 1960–93
HCFA Nursing Home 8.3%∗ 4.9% 1972–93
NHA-BEA Nursing Home 8.0%∗ 5.2% 1972–93
HCFA Home Health 8.3%∗ 5.7% 1972–93
PPI: Drugs and Pharmaceuticals −2.8%∗ −0.5% 0.0% 5.4% 6.5% 1947–93
PPI: X-Ray/Electromedical 8.5%∗ 1.7% 1971–93
PPI Hospital Services 4.0%∗ 1992–93
∗Data available for only part of the period (see right-hand column for dates).
Notes: All series are discussed in text, except the ﬁve MCPI components. The time periods approximately delineate periods in which medical prices
were subject to distinctive inﬂuences, as follows: 1935–1951: moderate technological change, most payments made out-of-pocket by patients, Great
Depression, World War II; 1951–1965: faster technological change, rapid growth of private medical insurance; 1965–1969: introduction of Medicare and
Medicaid; 1969–1980: high general inﬂation, low economic growth, rapid technological progress; 1980–1993: lower general inﬂation.     
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Personal Consumption Expenditures (PCE), Fixed-Weight Index,
Medical Component—Coverage: Payments for individuals’ medical care—
approximately 88 percent of national health expenditures. Includes payments
made by individuals and by public and private insurance programs. Does not in-
clude expenditures such as medical research and certain construction expenses.
Purpose: PCE comprises part of the National Income and Product Accounts,
and ﬁxed-weight price indexes are produced for an array of NIPA segments.
Years/Periodicity: 1929–1946/annual; 1947–present/quarterly. Source: U.S.
Commerce Department, Bureau of Economic Analysis. Reported: Survey of
Current Business. References: Getzen (1992), p. 96. Miscellaneous: The BEA
formerly produced a deﬂator of the PCE medical component, but these data
are no longer distributed.
Personal Health Care Expenditures (PHCE) Deﬂator—Coverage:
Includes public and private spending for direct health and medical services to
individuals. Included are expenditures for hospital care, physician services, den-
tal services, other professional services, drugs and other medical nondurables,
vision products and other medical durables, and nursing home care. Does
not include medical research, construction of medical facilities, public health
activities (e.g., disease prevention and control), program administration, and
the net cost of private health insurance. Purpose: To provide a broad-based
measure of medical care inﬂation that addresses some of the methodological
problems inherent in the MCPI—the CPI’s narrow expenditure base, for ex-
ample. Years/Periodicity: 1960–1991/annual. Source: Health Care Financing
Administration (HCFA). Reported: Health Care Financing Review. Refer-
ences: Letsch (1993).
HCFA Medicare Economic Index (MEI)—Coverage: Inputs to physi-
cian ofﬁce services (roughly 25 percent of national health expenditures), plus
an adjustment for economy-wide productivity growth. Inputs include physician
earnings, nonphysician earnings, ofﬁce expenses, medical materials and sup-
plies, professional liability costs, medical equipment, and some other goods and
services. Purpose: Used in annual updates of Medicare’s physician fee sched-
ule. The Secretary of Health and Human Services considers the MEI in rec-
ommending a new schedule to Congress. If Congress takes no action, the MEI
is used in calculating an automatically updated schedule. Years/Periodicity:
1980–present/quarterly; ten-year forecasts. Source: Health Care Financing Ad-
ministration (HCFA). Reported: Federal Register. References: For a fuller
description of the data sources and of the Medicare Economic Index in gen-
eral, see Ofﬁce of the Federal Register (1992, 1993) and Freeland, Chulis,
Arnett, and Brown (1991). Miscellaneous: By congressional intent, the MEI is
backward-looking rather than forward-looking because Congress believed that
increases in Medicare reimbursements should follow, rather than lead, inﬂation.
AHA Hospital Market Basket Index—Coverage: Hospital expendi-
tures—roughly 40 percent of national health expenditures in 1991. It is an input     
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price index for hospitals, measuring the changes in prices of hospital inputs—
the goods and services hospitals buy. Purpose: To serve as a guideline in
contract negotiations between hospitals and their contractors. Deﬂates hospital
expenditures over time in order to produce measures of real hospital spend-
ing growth. Years/Periodicity: 1963–present/monthly. Source: The American
Hospital Association (AHA). Reported: Quarterly in AHA’s Economic Trends.
References: This index and the HCFA Hospital Market Basket Index are com-
pared in Dyer and Li (1990). Miscellaneous: Uses ﬁxed-expenditure weights
that do not vary over time.
HCFA Prospective Payment System (PPS) Hospital Input Price
Index—Coverage: Hospital expenditures—roughly 40 percent of national
health expenditures in 1991. Input price index for hospitals. Measures the
changes in prices of the goods and services hospitals buy as inputs into their
production of goods and services. Used in the Medicare PPS update formula to
adjust hospital reimbursements for year-to-year inﬂation. Purpose: To provide
a regulatory baseline for adjusting the schedule of fees paid to hospitals under
Medicare and Medicaid. Years/Periodicity: 1986–present/quarterly. Backcast
data also have been produced for 1980–1986. Source: Health Care Financing
Administration (HCFA). Reported: Federal Register. References: Ofﬁce of
the Federal Register (1990); Freeland, Anderson, and Schendler (1979); Free-
land, Chulis, Brown et al. (1991), Freeland and Maple (1992). The HCFA and
AHA indexes are compared in Dyer and Li (1990). Miscellaneous: Uses ﬁxed-
quantity weights, where the quantities are ﬁxed from a base year but relative
importance shares change over time as prices change.
HCFA Hospital Transaction Output Price Index—Coverage: Esti-
mates the price of hospital outputs rather than inputs. To do so, the index uses
list price data to estimate transaction price data. Purpose: Seeks to measure
the rate of growth in transaction prices (rather than list prices) for hospital
goods and services. Because of increasing volume discounts for large pur-
chasers, list prices may overstate the actual growth in costs. Years/Periodicity:
1960–1993/annual. Source: Health Care Financing Administration (HCFA).
Reported: Not formally reported, but available through HCFA. References:
Fisher (Spring 1992, Fall 1992). Miscellaneous: There are two versions of this
index. One uses patient revenues, while the other uses total revenues, of which
patient revenues are only a part.
HCFA Regulation Skilled Nursing Home Input Price Index—Cover-
age: A market basket of the most commonly used nursing home inputs—
approximately 8 percent of national health expenditures. Purpose: To
reimburse skilled nursing facilities’ inpatient routine service costs under
Medicare. Years/Periodicity: 1972–present/quarterly. Source: Health Care
Financing Administration (HCFA). Reported: Biannually in the Federal
Register. References: Ofﬁce of the Federal Register (October 7, 1992).     
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National Health Accounts–Bureau of Economic Analysis (NHA–BEA)
Nursing Home Input Price Index with Capital Costs—Coverage: Inputs,
including capital, for the production of nursing home services. Purpose: To
estimate and project growth in nursing home prices while holding constant con-
tent of per-diem services, productivity, and proﬁt margins. Years/Periodicity:
1972–present/quarterly. Source: Health Care Financing Administration
(HCFA). Reported: Available on request from HCFA, Ofﬁce of the Actuary.
HCFA Regulation Home Health Agency Input Price Index—Coverage:
Goods and services used in producing home health care services—just over 1
percent of national health expenditures. Purpose: To determine reimbursement
limits under Medicare. Years/Periodicity: 1972–present/quarterly. Source:
Health Care Financing Administration (HCFA). Reported: Periodically in the
Federal Register. References: Federal Register (July 7, 1992).
Producer Price Index (PPI): individual medical components—Cover-
age: Medical goods sold by producers, including both intermediate and ﬁnal
goods. The PPI covers goods used as inputs to medical care, though there is
no aggregate index of medical producer prices. Two of the most important
categories are drugs and pharmaceuticals and X-ray and electromedical ma-
chinery. Purpose: To construct the overall PPI. Years/Periodicity: Drugs and
pharmaceuticals: 1947–present/monthly; X-ray and electromedical machinery:
1971–present/monthly. Source: U.S. Department of Labor, Bureau of Labor
Statistics. Reported: Producer Price Indexes monthly publication of data. Ref-
erences: Various PPI releases from the BLS. Miscellaneous: Traditionally, the
PPI has covered only goods, so much of the medical care industry has been
excluded. However, several areas of medical services have recently been added
to the PPI’s coverage (see PPI—Hospitals, below).
Producer Price Index (PPI) Price Indexes for Hospitals—Coverage:
These indexes for various classes of hospitals (general, psychiatric, etc.) are
based on output data—the revenues paid to hospitals for an average hospital stay
or outpatient treatment. Purpose: In 1993, the BLS began producing indexes
of hospital prices as part of a long-range plan to incorporate service industries
into the PPI. Years/Periodicity: 1993–present/monthly. Source: U.S. Depart-
ment of Labor, Bureau of Labor Statistics. Reported: Producer Price Indexes
monthly data publication. References: U.S. Department of Labor (1993), p. 5.
Miscellaneous: Similar indexes have been or will be introduced in 1994 for
physician services, medical laboratories, and nursing care facilities.     
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